Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET New York, NY, (February 28, 2024) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along wit ...